Lenalidomide

Lenalidomide binds to the cereblon protein, part of an E3 ubiquitin ligase complex, changing the complex’s target profile. This leads to the degradation of transcription factors Ikaros and Aiolos, which reduces malignant cell growth, enhances immune‑mediated tumor cell killing, and blocks new blood‑vessel formation that tumors need.

The dose of Lenalidomide is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and other patient‑specific factors. Only a qualified healthcare professional should determine the appropriate dosage and schedule.

Lenalidomide is classified as Pregnancy Category X because it can cause fetal harm. It is contraindicated in pregnant women and should not be used by women who are breastfeeding. Effective contraception is required for both male and female patients during treatment and for a defined period after the last dose.

To request Lenalidomide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide belongs to the class of immunomodulatory imide drugs, offering a distinct mechanism that combines anti‑angiogenic, immunostimulatory, and direct anti‑tumor effects. Compared with proteasome inhibitors or monoclonal antibodies, it provides an oral administration route and is often used in combination regimens to enhance overall response rates.

Lenalidomide tablets should be stored at ambient temperature below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging is tightly closed to maintain stability.

Lenalidomide is taken orally, usually with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole with a glass of water and follow any specific timing instructions provided by their healthcare provider.

The most serious risks include severe neutropenia that can lead to infections, deep‑vein thrombosis or pulmonary embolism, and the potential for secondary primary cancers. Patients should be monitored closely for signs of infection, clotting events, and any new malignancies during treatment.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to the drug, or patients with uncontrolled severe renal impairment unless dose adjustments are made. It is also contraindicated in patients who cannot adhere to required contraception measures.